Global Gastric Cancer Drug Market, By Type (Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor and Others), Treatment Type (Chemotherapy, Targeted Therapy, Immunotherapy, Surgery, Radiation therapy, Medication and Others), Drug Type (Doxorubicin Hydrochloride, Sunitinib Mitomycin, Imatinib, Fluorouracil, Trastuzumab and Others), Route of Administration (Oral and injectable), End- Users (Hospitals, Homecare, Specialty Clinics, Others), Country (U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East & Africa) Industry Trends and Forecast to 2028
Market Analysis and Insights : Global Gastric Cancer Drug Market
The gastric cancer drug market is expected to witness market growth at a rate of 14.95% in the forecast period of 2021 to 2028. Data Bridge Market Research report on gastric cancer drug market provides analysis and insights regarding the various factors expected to be prevalent throughout the forecast period while providing their impacts on the market’s growth. The increase in the prevalence of gastric cancer globally is escalating the growth of gastric cancer drug market.
Gastric cancer is also referred to as stomach cancer which is a type of cancer that begins when the cancer cells form in the inner lining of the stomach. This cancer generally progresses slowly. Indigestion, heartburn, slight nausea and loss of appetite among others are considered some of the early symptoms of this cancer. As the tumor progresses, the symptoms get worse such as vomiting, yellowish eyes or skin, stomach pain, swelling in stomach, weight loss, constipation and blood in stool.
The growing prevalence of lymphoma, adenocarcinoma, gastrointestinal stromal tumors, carcinoid tumors among population across the globe acts as one of the major factors driving the growth of gastric cancer drug market. The adoption of unhealthy lifestyle such as chronic consumption of tobacco products and alcohol and intake of diet with high fat, spicy food, less proteins consumption and physical inactivity accelerate the gastric cancer drug market growth. The growing number of cancer treatment centers and availability of combination therapies further influence the gastric cancer drug market. Additionally, improving healthcare system, growth in population, rise in healthcare expenditure and surge in investment for research projects positively affect the gastric cancer drug market. Furthermore, research and development activities and include innovations in treatment extend profitable opportunities to the gastric cancer drug market players in the forecast period of 2021 to 2028.
On the other hand, high cost associated with the treatments and lack of sufficient financial support from health insurance policies are the factors expected to obstruct the gastric cancer drug market growth. Patent expiry from many companies and introduction of generic drugs are projected to challenge the gastric cancer drug market in the forecast period of 2021-2028.
This gastric cancer drug market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on gastric cancer drug market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Gastric Cancer Drug Market Scope and Market Size
The gastric cancer drug market is segmented on the basis of type, treatment type, drug type, route of administration and end- users. The growth amongst these segments will help you analyze meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.
- On the basis of type, the gastric cancer drug market is segmented into adenocarcinoma, lymphoma, gastrointestinal stromal tumor, carcinoid tumor and others.
- On the basis of treatment type, the gastric cancer drug market is segmented into chemotherapy, targeted therapy, immunotherapy, surgery, radiation therapy, medication and others.
- On the basis of drug type, the gastric cancer drug market is segmented into doxorubicin hydrochloride, sunitinib mitomycin, imatinib, fluorouracil, trastuzumab and others.
- On the basis of route of administration, the gastric cancer drug market is segmented into oral and injectable.
- On the basis of end- users, the gastric cancer drug market is segmented into hospitals, homecare, specialty clinics and others.
Global Gastric Cancer Drug Market Country Level Analysis
The gastric cancer drug market is analyzed and market size insights and trends are provided by country, type, treatment type, drug type, route of administration and end-users as referenced above.
The countries covered in the global gastric cancer drug market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the gastric cancer drug market due to the rising prevalence of stomach cancer and the availability of advanced technology in cancer research and treatment centers.
The country section of the gastric cancer drug market report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as consumption volumes, production sites and volumes, import export analysis, price trend analysis, cost of raw materials, down-stream and upstream value chain analysis are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure growth Installed base and New Technology Penetration
The gastric cancer drug market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for gastric cancer drug market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on gastric cancer drug market. The data is available for historic period 2011-2019.
Competitive Landscape and Gastric Cancer Drug Market Share Analysis
The gastric cancer drug market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related to gastric cancer drug market.
The major players covered in the gastric cancer drug market report are mugene Limited, Otsuka Pharmaceuticals Co., Ltd, Immutep, F. Hoffmann-La Roche Ltd, Merck KGaA, Bristol-Myers Squibb Company, Novartis AG, Eli Lilly and Company, Sanofi S.A, Amgen Inc., Bayer AG, Celgene Corporation, Gilead Sciences, Inc., AstraZeneca, Ipsen Pharma, Takeda Pharmaceutical Company Limited, Samumed, LLC, Arbutus Biopharma, ASLAN Pharmaceuticals among other domestic and global players. Market share data is available for Global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
SKU-